A copolymer composed of poly(2-hydroxyethyl methacrylate) (PHEMA) and poly(ethylene glycol) diacrylate (PEGDA) (PHEMA-PEGDA) is structurally versatile. Its structure can be adjusted using the following porogens: water, sucrose, and benzyl alcohol. Using phase separation technique, a variety of surface architectures and pore morphologies were developed by adjusting porogen volume and type. The water and sucrose porogens were effective in creating porous and cytocompatible PHEMA-PEGDA scaffolds. When coated with collagen, the PHEMA-PEGDA scaffolds accommodated cell migration. The PHEMA-PEGDA scaffolds are easy to produce, non-toxic, and mechanically stable enough to resist fracture during routine handling. The PHEMA-PEGDA structures presented in this study may expedite the current research effort to engineer tissue scaffolds that provide both structural stability and biological activity.
Artificial corneas or keratoprostheses (KPros) are designed to replace diseased or damaged cornea. Although many synthetic KPros have been developed, current products are often inappropriate or inadequate for long term use due to ineffective host integration. This study presents an alternative approach of engineering a KPro that comprises a combination of poly (2-hydroxyethyl methacrylate) (PHEMA), poly (methyl methacrylate) (PMMA), and sodium chloride (NaCl) as porogen. Based on the core-skirt model for KPro, the porous outer portion of artificial cornea (skirt) was engineered by combining NaCl with HEMA and MMA monomers to promote tissue ingrowth from the host. The central optic (core) was designed to provide >85% light transmission in the visible wavelength range and securely attached to the skirt. Mechanical tensile data indicated that our KPro (referred to as salt porogen KPro) is mechanically stable to maintain its structure in the ocular environment and during implantation. Using human corneal fibroblasts (HCFs), we demonstrate that the cells grew into the pores of the skirt and proliferated, suggesting biointegration is adequately achieved. This novel PHEMA-PMMA copolymeric salt porogen KPro may offer a cornea replacement option that leads to minimal risk of corneal melting by permitting sufficient tissue ingrowth and mass transport.
Background: IGV-001 is a novel immunotherapy that combines irradiated patient-derived glioblastoma tumor cells and an antisense oligonucleotide against insulin-like growth factor type 1 receptor (IMV-001) in biodiffusion chambers (BDC). We recently reported that IGV-001-treated newly diagnosed glioblastoma patients with methylated O6-methylguanine-DNA methyl-transferase promoter had a median progression free survival of 38.4 months compared with 8.3 months in historical standard-of-care-treated patients (P=0.0008). We have now found activity with the equivalent murine approach in multiple cancer models, highlighting the transformative potential of this immunotherapeutic platform beyond glioblastoma. Methodology: We utilized several murine models including the ID8-luciferase (-Luc) intraperitoneal ovarian cancer and Hepa1-6-Luc hepatocellular carcinoma orthotopic model. BDC containing saline or 1x106 IMV-001-treated tumor cells (hereon IOV-001 and IHV-001, respectively) were implanted in flanks of C57BL/6 mice and explanted 48 h later, as per glioblastoma clinical protocol. Tumor challenge for all models was conducted 28d after chamber implantation. Mice were monitored for survival and tumor growth, as determined by bioluminescence intensity. Cytokine assays and immunophenotyping were conducted. Results: 60% of IOV-001-treated mice were alive 58d post-tumor challenge, compared to only 19% of mice in the saline group (MST=37d, p=0.004). In the Hepa1-6 model, 50% of IHV-001-treated mice were alive by 100d post-tumor challenge (MST = 60.5d). In comparison, there were no survivors in the saline group beyond 28d (MST = 18d; p = 0.004). Most of the long-term survivors had undetectable tumor; a fraction showed some level of tumor burden which rose and fell, demonstrating immune control. Circulating IFNγ was significantly higher in IOV-001-treated mice compared to controls on 1d post-tumor challenge (p<0.001) and trended higher in those receiving IHV-001 14d after tumor challenge. Positive correlations were found between percentages of CD8+PD1+and CD4+TIM3+, and tumor burden in IOV-001-treated mice. On 14d, PD1+ expression in both CD4+ and CD8+ T cell subsets was significantly lower in surviving mice treated with IHV-001. Improved survival using this approach was also observed in the Pan02 orthotopic pancreatic model. Latest data will be presented. Conclusions: These data support the antitumor activity of this novel immunotherapeutic platform in multiple cancers beyond glioblastoma. Results suggest that efficacy is associated with a systemic immunological response, resulting in generation of Th1 antitumor cytotoxic T cells. Future studies are seeking to resolve the factors triggering good v. poor responses using phenotypic evaluation of T cell activation/exhaustion markers and Th1/Th2 cytokine production. Citation Format: Jenny Zilberberg, Amelia Zellander, Christopher Uhl, Christopher Cultrara, Kenneth kirby, Essam Elazaq, Charles B. Scott, David W. Andrews, Mark Exley. Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 626.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.